Somaxon CEO Kenneth M. Cohen has announced this resignation, effective December 31, 2007. The company's non-executive board chairman David F. Hale will serve as interim CEO until a permanent replacement for Cohen is hired. Specific reasons for Cohen's resignation were not outlined in the announcement, though the company noted that "management changes are part of a transition plan." Somaxon is based in San Diego, CA and is developing psychiatry and neurology treatments.
- see Somaxon's release